Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $7.5 price tar...
HC Wainwright & Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and raises the price target f...
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $...
Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit...
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of...
